Heron Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.09) Per Share, Capital One Financial Forecasts (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for Heron Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Capital One Financial analyst T. Chiang forecasts that the biotechnology company will post earnings per share of ($0.09) for the quarter. Capital One Financial currently has a “Overweight” rating and a $6.00 target price on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.22) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.28) EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.47 EPS.

A number of other research firms have also commented on HRTX. StockNews.com upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Heron Therapeutics in a research report on Thursday, April 11th.

Heron Therapeutics Trading Down 3.8 %

Shares of NASDAQ:HRTX opened at $2.55 on Thursday. The firm’s 50 day moving average is $2.75 and its two-hundred day moving average is $1.96. Heron Therapeutics has a 52 week low of $0.50 and a 52 week high of $3.22. The firm has a market capitalization of $383.34 million, a P/E ratio of -2.97 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.08. The business had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rubric Capital Management LP lifted its holdings in Heron Therapeutics by 127.3% in the third quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company’s stock valued at $27,515,000 after buying an additional 14,963,503 shares during the period. Monaco Asset Management SAM raised its holdings in Heron Therapeutics by 219.5% in the fourth quarter. Monaco Asset Management SAM now owns 2,226,475 shares of the biotechnology company’s stock worth $3,785,000 after purchasing an additional 1,529,567 shares during the period. Congress Park Capital LLC raised its holdings in Heron Therapeutics by 205.3% in the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock worth $3,058,000 after purchasing an additional 1,209,500 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in Heron Therapeutics by 100.0% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,060,000 after purchasing an additional 1,000,000 shares during the period. Finally, Tejara Capital Ltd raised its holdings in Heron Therapeutics by 28.6% in the third quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock worth $2,173,000 after purchasing an additional 469,548 shares during the period. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.